EHF
MCID: EBL001
MIFTS: 47

Ebola Hemorrhagic Fever (EHF)

Categories: Infectious diseases, Oral diseases, Rare diseases

Aliases & Classifications for Ebola Hemorrhagic Fever

MalaCards integrated aliases for Ebola Hemorrhagic Fever:

Name: Ebola Hemorrhagic Fever 12 59 15
Ebola Virus Disease 12 76 53 59 3
Hemorrhagic Fever, Ebola 44 73
Ebola Fever 59
Ehf 59

Characteristics:

Orphanet epidemiological data:

59
ebola hemorrhagic fever
Prevalence: <1/1000000 (Europe); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Ebola Hemorrhagic Fever

Disease Ontology : 12 A viral infectious disease that is a hemorrhagic fever, has material basis in Zaire ebolavirus, has material basis in Sudan ebolavirus, has material basis in Cote d'Ivoire ebolavirus, or has material basis in Bundibugyo ebolavirus, which are transmitted by contact with the body fluids of an infected animal or person, transmitted by contaminated fomites, or transmitted by infected medical equipment. The infection has symptom fever, has symptom headache, has symptom joint pain, has symptom muscle aches, has symptom sore throat, has symptom weakness, has symptom diarrhea, has symptom vomiting, has symptom stomach pain, has symptom rash, has symptom red eyes, has symptom hiccups, and has symptom internal and external bleeding.

MalaCards based summary : Ebola Hemorrhagic Fever, also known as ebola virus disease, is related to stomatitis and marburg hemorrhagic fever, and has symptoms including fever and pruritus. An important gene associated with Ebola Hemorrhagic Fever is F5 (Coagulation Factor V). The drugs Immunologic Factors and Vaccines have been mentioned in the context of this disorder. Affiliated tissues include eye, liver and kidney, and related phenotypes are seizures and nausea and vomiting

Wikipedia : 76 Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF) or simply Ebola, is a viral... more...

Related Diseases for Ebola Hemorrhagic Fever

Graphical network of the top 20 diseases related to Ebola Hemorrhagic Fever:



Diseases related to Ebola Hemorrhagic Fever

Symptoms & Phenotypes for Ebola Hemorrhagic Fever

Human phenotypes related to Ebola Hemorrhagic Fever:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 59 32 occasional (7.5%) Occasional (29-5%) HP:0001250
2 nausea and vomiting 59 32 frequent (33%) Frequent (79-30%) HP:0002017
3 renal insufficiency 59 32 occasional (7.5%) Occasional (29-5%) HP:0000083
4 proteinuria 59 32 occasional (7.5%) Occasional (29-5%) HP:0000093
5 fatigue 59 32 hallmark (90%) Very frequent (99-80%) HP:0012378
6 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
7 thrombocytopenia 59 32 occasional (7.5%) Occasional (29-5%) HP:0001873
8 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
9 chemosis 59 32 frequent (33%) Frequent (79-30%) HP:0012375
10 coma 59 32 occasional (7.5%) Occasional (29-5%) HP:0001259
11 gastrointestinal hemorrhage 59 32 frequent (33%) Frequent (79-30%) HP:0002239
12 chest pain 59 32 frequent (33%) Frequent (79-30%) HP:0100749
13 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
14 epistaxis 59 32 occasional (7.5%) Occasional (29-5%) HP:0000421
15 macule 59 32 occasional (7.5%) Occasional (29-5%) HP:0012733
16 recurrent pharyngitis 59 32 hallmark (90%) Very frequent (99-80%) HP:0100776
17 skin rash 59 32 occasional (7.5%) Occasional (29-5%) HP:0000988
18 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
19 acute hepatic failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0006554
20 gingival bleeding 59 32 occasional (7.5%) Occasional (29-5%) HP:0000225
21 lethargy 59 32 occasional (7.5%) Occasional (29-5%) HP:0001254
22 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
23 metrorrhagia 59 32 occasional (7.5%) Occasional (29-5%) HP:0100608
24 cardiac arrest 59 32 frequent (33%) Frequent (79-30%) HP:0001695
25 leukopenia 59 32 frequent (33%) Frequent (79-30%) HP:0001882
26 restrictive ventilatory defect 59 32 frequent (33%) Frequent (79-30%) HP:0002091
27 abnormal bleeding 59 Occasional (29-5%)

UMLS symptoms related to Ebola Hemorrhagic Fever:


fever, pruritus

Drugs & Therapeutics for Ebola Hemorrhagic Fever

Drugs for Ebola Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1
2 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
3
Coal tar Approved Phase 2, Phase 3,Phase 1 8007-45-2
4
Loperamide Approved Phase 2, Phase 3 53179-11-6 3955
5 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
6 Krestin Phase 3,Phase 2,Phase 1
7 Iron-Dextran Complex Phase 3,Phase 2,Phase 1
8 Anti-Bacterial Agents Phase 2, Phase 3,Phase 1
9 Anti-Infective Agents Phase 2, Phase 3,Phase 1
10 Dermatologic Agents Phase 2, Phase 3,Phase 1
11 Keratolytic Agents Phase 2, Phase 3,Phase 1
12
Angiotensin II Approved, Investigational Phase 1, Phase 2 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
13
Irbesartan Approved, Investigational Phase 1, Phase 2 138402-11-6 3749
14
Azithromycin Approved Phase 1, Phase 2 83905-01-5 55185 447043
15
Sunitinib Approved, Investigational Phase 1, Phase 2 557795-19-4, 341031-54-7 5329102
16
Lumefantrine Approved Phase 2 82186-77-4 6437380
17
Artemether Approved Phase 2 71963-77-4 119380 68911
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2,Phase 2
19 Atorvastatin Calcium Phase 1, Phase 2 134523-03-8
20 Calcium, Dietary Phase 1, Phase 2
21 Anticholesteremic Agents Phase 1, Phase 2,Phase 2
22 Lipid Regulating Agents Phase 1, Phase 2,Phase 2
23 Angiotensin II Type 1 Receptor Blockers Phase 1, Phase 2
24 Protein Kinase Inhibitors Phase 1, Phase 2
25 Angiogenesis Modulating Agents Phase 1, Phase 2
26 Antihypertensive Agents Phase 1, Phase 2
27
Erlotinib Hydrochloride Phase 1, Phase 2 183319-69-9 176871
28 Angiogenesis Inhibitors Phase 1, Phase 2
29 Angiotensinogen Phase 1, Phase 2
30 Angiotensin Receptor Antagonists Phase 1, Phase 2
31 Hypolipidemic Agents Phase 1, Phase 2,Phase 2
32 Antimetabolites Phase 1, Phase 2,Phase 2
33 Antiviral Agents Phase 2,Phase 1
34 Antidiarrheals Phase 2
35 Artemether-lumefantrine combination Phase 2
36 Antibiotics, Antitubercular Phase 2,Phase 1
37 Vitamins Phase 2
38 Antibodies Phase 1, Phase 2
39 Immunoglobulins Phase 1, Phase 2
40 Anti-Inflammatory Agents Phase 2
41 Adjuvants, Immunologic Phase 1
42 Radiation-Protective Agents Phase 1
43 Protective Agents Phase 1
44 interferons Phase 1
45 Interferon Inducers Phase 1
46 Antibodies, Monoclonal Phase 1
47 Cathartics Phase 1
48 Carboxymethylcellulose Sodium Phase 1
49 Poly ICLC Phase 1
50 Laxatives Phase 1

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 International Multicenter Study of the Immunogenicity of Medicinal Product GamEvac-Combi Recruiting NCT03072030 Phase 4
2 Emergency Evaluation of Convalescent Plasma for Ebola Viral Disease (EVD) in Guinea Completed NCT02342171 Phase 2, Phase 3
3 STRIVE (Sierra Leone Trial to Introduce a Vaccine Against Ebola) Completed NCT02378753 Phase 2, Phase 3
4 Providing Additional Information on the Safety and Effectiveness of an Ebola Vaccine Completed NCT03161366 Phase 3
5 Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) Completed NCT02503202 Phase 3
6 A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543268 Phase 3
7 A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA‐BN‐Filo in Healthy Adult Participants Completed NCT02543567 Phase 3
8 Investigational Therapeutics for the Treatment of People With Ebola Virus Disease Recruiting NCT03719586 Phase 2, Phase 3 ZMapp;Remdesivir;MAb114;REGN-EB3
9 Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo Recruiting NCT02661464 Phase 3
10 Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo During Implementation of Stages 1 and 2 Active, not recruiting NCT02509494 Phase 3
11 Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) Withdrawn NCT02307591 Phase 2, Phase 3 Best Supportive Care;Best Supportive Care + Amiodarone
12 Multiple Treatments for Ebola Virus Disease (EVD) Unknown status NCT02380625 Phase 1, Phase 2 Azithromycin;Sunitinib and Erlotinib;Atorvastatin and Irbesartan
13 A Clinical Trial to Evaluate the Recombinant Human Type5 Adenovirus Vector Based Ebola Virus Disease Vaccine Completed NCT02575456 Phase 2
14 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Adults Completed NCT02485301 Phase 2 Placebo
15 Efficacy of Favipiravir Against Ebola (JIKI) Completed NCT02329054 Phase 2 Favipiravir
16 Efficacy of Favipiravir Against Severe Ebola Virus Disease Completed NCT02662855 Phase 2 Favipiravir
17 A Study to Evaluate the Safety and Immunogenicity of a Candidate Ebola Vaccine in Children Completed NCT02548078 Phase 2
18 A Clinical Trial on the Candidate Vaccine cAd3-EBOZ in Healthy Adults in Switzerland Completed NCT02289027 Phase 1, Phase 2
19 A Double-blind Randomized Placebo-controlled Study of Safety and Immunogenicity of GamEvac-Lyo Completed NCT03333538 Phase 1, Phase 2
20 A Study to Assess Safety Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults Completed NCT02416453 Phase 2
21 VSV-ZEBOV Geneva Vaccine Trial Completed NCT02287480 Phase 1, Phase 2
22 Partnership for Research on Ebola VACcinations Recruiting NCT02876328 Phase 2
23 African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola Recruiting NCT03031912 Phase 2
24 GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen Recruiting NCT02818582 Phase 2 GS-5734
25 Yellow Fever Vaccine on Statin/ Non Statin Subjects Recruiting NCT03116802 Phase 2 Stamaril (live attenuated yellow fever vaccine)
26 Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) Active, not recruiting NCT02344407 Phase 2
27 Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults Active, not recruiting NCT02564523 Phase 2
28 Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo Active, not recruiting NCT02598388 Phase 2
29 Immunogenicity of Recombinant Vesicular Stomatitis Vaccine for Ebola-Zaire (rVSV[Delta]G-ZEBOV-GP) for Pre-Exposure Prophylaxis (PREP) in People at Potential Occupational Risk for Ebola Virus Exposure Enrolling by invitation NCT02788227 Phase 2 rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)
30 Putative Investigational Therapeutics in the Treatment of Patients With Known Ebola Infection Suspended NCT02363322 Phase 1, Phase 2 ZMApp
31 Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen Terminated NCT02739477 Phase 2 Favipiravir
32 An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease Withdrawn NCT02271347 Phase 2 CMX001
33 A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya. Unknown status NCT02296983 Phase 1
34 A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z Unknown status NCT02451891 Phase 1
35 A Phase I Clinical Trial to Evaluate the Ebola Adenovirus Vector Vaccine (Ad5-EBOV) in Healthy Adults. Completed NCT02326194 Phase 1
36 Trial to Evaluate Safety and Immunogenicity of an Ebola Zaire Vaccine in Healthy Adults Completed NCT02718469 Phase 1
37 Evaluating an Ebola and a Marburg Vaccine in Uganda Completed NCT00997607 Phase 1
38 A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo Completed NCT02240875 Phase 1
39 A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization Completed NCT02533791 Phase 1
40 Clinical Trial of Ebola Vaccines cAd3-EBO, cAd3-EBOZ and MVA-EbolaZ in Healthy Adults in Uganda Completed NCT02354404 Phase 1
41 Phase 1 Trial of Ebola Vaccine in Mali Completed NCT02267109 Phase 1
42 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine (rVSVΔG-ZEBOV-GP) Completed NCT02283099 Phase 1
43 Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy Subjects Completed NCT02370589 Phase 1
44 Phase I Trial to Assess the Safety, Tolerability and Immunogenicity of a Ebola Virus Vaccine Completed NCT02374385 Phase 1
45 A Phase I Trial to Evaluate Ad5-EBOV in Healthy Adult Africans in China. Completed NCT02401373 Phase 1
46 Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) Completed NCT02280408 Phase 1
47 A Study to Assess Ebola Vaccines ChAd3-EBO-Z and Ad26.ZEBOV Completed NCT02495246 Phase 1
48 Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) Completed NCT02314923 Phase 1
49 Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) Completed NCT02269423 Phase 1
50 An Open Study of the Safety and Pharmacokinetics of a Medicinal Product for Emergency Prevention of Ebola Completed NCT03428347 Phase 1

Search NIH Clinical Center for Ebola Hemorrhagic Fever

Cochrane evidence based reviews: hemorrhagic fever, ebola

Genetic Tests for Ebola Hemorrhagic Fever

Anatomical Context for Ebola Hemorrhagic Fever

MalaCards organs/tissues related to Ebola Hemorrhagic Fever:

41
Eye, Liver, Kidney, Testes, Skin, Lung, Breast

Publications for Ebola Hemorrhagic Fever

Articles related to Ebola Hemorrhagic Fever:

(show top 50) (show all 877)
# Title Authors Year
1
Immunogenicity of a Candidate Ebola Hemorrhagic Fever Vaccine in Mice Based on Controlled In Vitro Expression of Ebolavirus Glycoprotein. ( 30095362 )
2018
2
Clinical Manifestations and Pathogenesis of Uveitis in Ebola Virus Disease Survivors. ( 29993303 )
2018
3
Virus-encoded miRNAs in Ebola virus disease. ( 29691416 )
2018
4
Impact of infection prevention and control training on health facilities during the Ebola virus disease outbreak in Guinea. ( 29699538 )
2018
5
Cross-Sectional Study on Acceptability of the Media Channels About Ebola Virus Disease in Guangzhou, China. ( 29742004 )
2018
6
Changes in risk perceptions during the 2014 Ebola virus disease epidemic: results of two consecutive surveys among the general population in Lower Saxony, Germany. ( 29764410 )
2018
7
Symptom-Based Ebola Risk Score for Ebola Virus Disease, Conakry, Guinea. ( 29774864 )
2018
8
Enacting high reliability principles while caring for people with Ebola Virus Disease. ( 29784444 )
2018
9
Multimodal Imaging and Spatial Analysis of Ebola Retinal Lesions in 14 Survivors of Ebola Virus Disease. ( 29800941 )
2018
10
Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. ( 29860496 )
2018
11
Response to the Ebola virus disease outbreak in the Democratic Republic of the Congo. ( 29916371 )
2018
12
Knowledge, Attitude, and Practice Regarding Ebola Virus Disease and Related Factors among International Students of Tehran University of Medical Sciences, 2015. ( 29922628 )
2018
13
Broad Neutralizing Activity Against Ebolaviruses Lacking the Mucin-Like Domain in Convalescent Plasma Specimens From Patients With Ebola Virus Disease. ( 29939289 )
2018
14
Ebola virus disease: assessment of knowledge, attitude and practice of nursing students of a Nigerian University. ( 29977258 )
2018
15
T-Cell Receptor Diversity and the Control of T-Cell Homeostasis Mark Ebola Virus Disease Survival in Humans. ( 29986035 )
2018
16
Effects of Ebola Virus Disease education on student health professionals. ( 29986826 )
2018
17
Case Series of Severe Neurologic Sequelae of Ebola Virus Disease during Epidemic, Sierra Leone. ( 30014839 )
2018
18
Correlates of vaccine-induced protective immunity against Ebola virus disease. ( 30041831 )
2018
19
Ebola virus disease: 11 323 deaths later, how far have we come? ( 30047373 )
2018
20
Outbreak of Ebola virus disease in the Democratic Republic of the Congo, April-May, 2018: an epidemiological study. ( 30047375 )
2018
21
Post-Ebola Syndrome among Ebola Virus Disease Survivors in Montserrado County, Liberia 2016. ( 30050920 )
2018
22
Intensive care support and clinical outcomes of patients with Ebola virus disease (EVD) in West Africa. ( 30062576 )
2018
23
Serological Investigation of Laboratory-Confirmed and Suspected Ebola Virus Disease Patients During the Late Phase of the Ebola Outbreak in Sierra Leone. ( 30066045 )
2018
24
The impact of the Ebola virus disease (EVD) epidemic on agricultural production and livelihoods in Liberia. ( 30071016 )
2018
25
Agent-Based Modeling and Simulation of Nosocomial Infection among Healthcare Workers during Ebola Virus Disease Outbreak in Sierra Leone. ( 30078788 )
2018
26
Kinetics of Soluble Mediators of the Host Response in Ebola Virus Disease. ( 30101349 )
2018
27
Prevention of Ebola virus disease through vaccination: where we are in 2018. ( 30104048 )
2018
28
Neurological, cognitive, and psychological findings among survivors of Ebola virus disease from the 1995 Ebola outbreak in Kikwit, Democratic Republic of Congo: a cross-sectional study. ( 30107392 )
2018
29
Travelers' Actual and Subjective Knowledge about Risk for Ebola Virus Disease. ( 30124406 )
2018
30
Implications of the Ebola virus disease outbreak in Guinea: Qualitative findings to inform future health and nutrition-related responses. ( 30138407 )
2018
31
Barriers to supportive care during the Ebola virus disease outbreak in West Africa: Results of a qualitative study. ( 30183718 )
2018
32
French guidelines for the outpatient management of Ebola virus disease: Applicability by family physicians. ( 30197019 )
2018
33
Status of Ebola Virus Disease (EVD) preventive practices among Health care workers (HCWs) in Benin City: a year after disease containment in Nigeria. ( 30197741 )
2018
34
Ebola Virus Disease Preparations Do Not Protect the United States Against Other Infectious Outbreaks. ( 30207757 )
2018
35
An Exploration of the Spatiotemporal and Demographic Patterns of Ebola Virus Disease Epidemic in West Africa Using Open Access Data Sources. ( 30224832 )
2018
36
Drug Repurposing for Ebola Virus Disease: Principles of Consideration and the Animal Rule. ( 30244014 )
2018
37
Correction: Implications of the Ebola virus disease outbreak in Guinea: Qualitative findings to inform future health and nutrition-related responses. ( 30281637 )
2018
38
Environmental temperature and case fatality of patients with Ebola virus disease in Sierra Leone and Liberia, 2014-2015: a retrospective cohort study. ( 30307686 )
2018
39
Adherence to Universal Travel Screening in the Emergency Department During Epidemic Ebola Virus Disease. ( 30342859 )
2018
40
Stillbirths and neonatal deaths surveillance during the 2014-2015 Ebola virus disease outbreak in Sierra Leone. ( 30467853 )
2018
41
Exploratory investigation of region level risk factors of Ebola Virus Disease in West Africa. ( 30488016 )
2018
42
FRONTLINE: a new treatment facility for Ebola virus disease. ( 30527407 )
2018
43
Equine-origin immunoglobulin fragments protects nonhuman primates from Ebola virus disease. ( 30541860 )
2018
44
Knowledge, risk perception and mitigation measures towards Ebola virus disease by potentially exposed bushmeat handlers in north-central Nigeria: Any critical gap? ( 28771956 )
2018
45
A Risk Analysis Approach to Prioritizing Epidemics: Ebola Virus Disease in West Africa as a Case Study. ( 28810081 )
2018
46
Sexual behaviours in the context of the Ebola virus disease (EVD) in Ghana. ( 28929904 )
2018
47
Evidence-based guidelines for supportive care of patients with Ebola virus disease. ( 29054555 )
2018
48
Experiences of Response Measures against the 4 Suspected Cases of Ebola Virus Disease from West Africa in the National Center for Global Health and Medicine, Tokyo, Japan. ( 29093311 )
2018
49
Ebola virus disease: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine. ( 29128378 )
2018
50
Prognostic and Predictive Factors of Ebola Virus Disease Outcome in Elderly People during the 2014 Outbreak in Guinea. ( 29141743 )
2018

Variations for Ebola Hemorrhagic Fever

Expression for Ebola Hemorrhagic Fever

Search GEO for disease gene expression data for Ebola Hemorrhagic Fever.

Pathways for Ebola Hemorrhagic Fever

GO Terms for Ebola Hemorrhagic Fever

Sources for Ebola Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....